Leuprolide plus donepezil may stabilize memory loss in Alzheimer's disease
the ONA take:
According to a new study published in the Journal of Alzheimer's Disease, researchers have found that leuprolide, a drug commonly used for androgen deprivation therapy for patients with prostate cancer, stabilized memory loss for a year in women with Alzheimer's disease.
For the study, researchers enrolled 109 women with mild to moderate Alzheimer's disease. Some women were treated with high-dose leuprolide acetate and donepezil, an acetylcholinesterase inhibitor that treats symptoms of Alzheimer's disease.
Other patients received an acetylcholinesterase inhibitor plus low-dose leuprolide or placebo. Results showed that those treated with donepezil and high-dose leuprolide had nearly no decline in their ADAS-cog score, a memory test, while those treated with an acetylcholinesterase inhibitor plus low-dose leuprolide or placebo experienced declines after 1 year.
Previous studies have suggested the leuprolide has protective benefits for Alzheimer's disease. One study found that men treated with leuprolide for prostate cancer were 34-55% less likely to develop Alzheimer's disease compared with men who did not receive the injection.
The researchers suggest that this promising drug combination should be tested in patients with early and late stages of the disease, but because the company that initially conducted this research is now out of business, it is unclear whether this therapy will be further developed.
Leuprolide stabilized memory loss for a year in women with Alzheimer's disease.
Sign Up for Free e-newsletters
- Managing Chemo Brain in Pediatric Survivors of Childhood Cancer
- Aggressive Therapy Provides No Additional Advantage in Metastatic Prostate Cancer
- Excretion of Volatile Organic Compounds Higher in AYAs Using Vaping Products
- FDA, ASHP Actions to Prevent or Manage Chemotherapy Drug Shortages
- Risk for Cardiovascular Disease Higher in Survivors of Testicular Cancer
- Various Aspects of Palliative Care Focus Associated With Different Outcomes In Cancer
- Cost vs Benefits: The Controversy Over Proton Beam Radiotherapy
- Patient Expectations at Odds With Actual Outcomes for Radiotherapy in Breast Cancer
- Patients Desire More Online Tools and Access
- Metformin Plus Ruxolitinib: A Potential Therapeutic Alternative for Myeloproliferative Neoplasms
- Sexual Quality of Life Decreased During, After Chemotherapy for Digestive Cancers
- CHEMO-SUPPORT: A Nursing Intervention to Relieve Chemotherapy Symptom Burden
- Approach and Management of Checkpoint Inhibitor-related Immune Hepatitis
- Revised AJCC8 Demonstrates Superior Tumor Classification for HNCSCC
- Oral Androgen Receptor Inhibitor Granted FDA Approval for Nonmetastatic CRPC
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|